Dataset Information

Quinoxaline analog selectively inhibits MAP3K1, blocks IKK and NPM1 phosphorylation, and sensitizes pancreatic cancer to gemcitabine

ABSTRACT: Mitogen activated protein kinase kinase kinase 1 (MAP3K1), is involved in various cancer signaling networks including the NF-B, JNK, ERK, and p38 pathways. Functioning as a signaling kinase in these oncogenic pathways, MAP3K1 contributes to tumor growth and metastasis. Additionally, higher transcript levels of MAP3K1 in pancreatic patient tumors is associated with poorer 5-year survival, suggesting MAP3K1 is an attractive therapeutic target. Activation of inhibitor of nuclear factor NF-κB kinase subunit-β (IKK), an important phosphorylation target of MAP3K1, was shown to be important in pancreatic cancer (PC) disease onset and progression. We previously reported a quinoxaline analog, Analog 84, which inhibits IKK phosphorylation and downstream NF-B pathway activation. To improve the metabolic stability and bioavailability of Analog 84, we developed 51-106, which moved -F atom to block a site of potential metabolism. Using a chemoproteomics approach for kinome profiling, KiNativTM, we show 51-106 selectively binds to MAP3K1 in an ATP-competitive manner. Follow up studies show 51-106 inhibits downstream phosphorylation of IKK and blocks TNF-induced MAP3K1-IKK-mediated NF-B activity. Treatment of PC cell lines MiaPaCa2 and PANC-1 with 51-106 inhibits cell growth and migration with low micromolar potency. Utilizing 51-106 as a tool to study MAP3K1 signaling, we use phosphoproteomics analysis to show MAP3K1 inhibition leads to a dose dependent decrease in NPM1 T199 phosphorylation, suggesting NPM1 may play a role in MAP3K1 signaling. We observe a dose-dependent S-phase arrest in cells treated with 51-106, potentially linking MAP3K1 inhibition to a dysfunctional DNA damage response. Consistent with this observation, in combination studies, 51-106 synergistically inhibited growth with gemcitabine in LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre (KPC) cell lines in vitro and in KPC syngeneic orthotopic implantation mouse model of pancreatic cancer in vivo. Our data indicated that MAP3K1 inhibition may represent a promising therapeutic in PC. These findings underscore the need for further investigation into the molecular interactions and downstream effects of the MAP3K1-NPM1 signaling axis.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Cancer Cell Line, Epithelial Cell

DISEASE(S): Pancreatic Cancer

SUBMITTER: Akhilesh Pandey

LAB HEAD: Akhilesh Pandey

PROVIDER: PXD055363 | Pride | 2025-05-26

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	PANC1_18plex_Phospho_Eclipse_12F.pdResult	Other
	PANC1_18plex_Phospho_Eclipse_F1.raw	Raw
	PANC1_18plex_Phospho_Eclipse_F10.raw	Raw
	PANC1_18plex_Phospho_Eclipse_F11.raw	Raw
	PANC1_18plex_Phospho_Eclipse_F12.raw	Raw

Items per page:

1 - 5 of 27

Publications

A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network.

Boghean Lidia L Singh Sarbjit S Mangalaparthi Kiran K KK Kizhake Smitha S Umeta Lelisse L Wishka Donn D Grothaus Paul P Pandey Akhilesh A Natarajan Amarnath A

Molecules (Basel, Switzerland) 20250430 9

The quinoxaline core is found in several biologically active compounds, with Erdafitinib being the first FDA-approved quinoxaline derivative that targets a kinase and exhibits anti-cancer properties. We previously reported a quinoxaline analog (84) that displayed anti-cancer effects by inhibiting IKKβ, a key kinase in the NFκB pathway. Here, we present the synthesis of a regioisomer (51-106) and its characterization as a selective MAP3K1 inhibitor with improved metabolic sta ...[more]

PMID: 40363807

Similar Datasets

Project description:Classical Hodgkin lymphoma (cHL) is one of the most common malignant lymphomas. It is characterized by the presence of rare Hodgkin and Reed/Sternberg (HRS) cells embedded in an extensive inflammatory infiltrate. Constitutive activation of nuclear factor-kappaB (NF-kappaB) in HRS cells which transcriptionally regulates expression of multiple anti-apoptotic factors and pro-inflammatory cytokines plays a central role in the pathogenesis of cHL (1, 2). In non-stimulated condition, NF-kappaB proteins are rendered inactive by binding to their inhibitors (IkappaB s), which sequester them in the cytoplasm. Stimulation of multiple receptors activates the IkappaB kinase (IKK) complex that phosphorylates IkappaB at two specific serine residues, followed by its ubiquitination and proteasomal degradation, thereby releasing NF-kappaB proteins and allowing their nuclear translocation (3). Recently, two studies provided further insights into the molecular mechanisms of IKK activation upon TNF stimulation (4, 5). Activation of the IKK complex and subsequent NF-kappaB activation requires Lys63 polyubiquitination of RIP1, a kinase which is recruited to the receptor upon TNF stimulation. IKK-ï§ï (NEMO), the regulatory subunit of the IKK complex, specifically recognizes these Lys63-linked polyubiquitins attached to RIP1 and thereby activates IKK and NF-kappaB (4, 5). A20 is an ubiquitin-modifying enzyme that inhibits NF-kappaB activation in succession of tumor necrosis factor (TNF) receptor and Toll-like receptor induced signals (6-8). This enzyme removes Lys63 linked ubiquitin chains from RIP1 and adds Lys48 polyubiquitins to RIP1, thereby targeting this factor for proteasomal degradation, thus explaining the molecular mechanism of NF-kappaB inhibition by A20 (6). A20 likely inhibits NF-kappaB acitivity also by additional means, including interaction with TRAF1 and TRAF2 (9). SNP 6.0 array (Affymetrix) analyses were performed according to the manufacturer's directions on DNA extracted from three Hodgkin cell lines (L1236, HDLM-2, U-HO1), HapMap samples included in the Genotyping Console Software 3.0 were used as references.